Belite Bio (BLTE) Cash from Operations (2024 - 2025)

Belite Bio (BLTE) recorded quarterly Cash from Operations of 10385000.0 in Q4 2025, down 125.71% quarter-over-quarter from 4601000.0 in Q4 2024, and down 125.71% on a YoY basis from 40390012.68 in Q4 2024.

Belite Bio (BLTE) Cash from Operations (2024 - 2025) Analysis & Trends

Belite Bio's Cash from Operations history runs 2 years deep, the most recent figure standing at 10385000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -1.67 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -12.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.49 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.43 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 1.08 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 -10.39 Mn
Dec 31, 2025 -10.39 Mn
Dec 31, 2024 -4.60 Mn
Dec 31, 2024 -4.60 Mn